Literature DB >> 22878676

[Repetitive impulse-associated behavioral disorders in Parkinson's disease].

R Katzenschlager1, K S Goerlich, T van Eimeren.   

Abstract

Parkinson's disease (PD) is associated with a number of behavioral disorders which may cause considerable social, professional or financial problems. Impulse control disorders (ICDs), such as pathological gambling, binge eating, compulsive shopping and hypersexuality occur in approximately 13-14% of PD patients. Further behavioral disorders are the dopamine dysregulation syndrome (DDS), a substance dependence characterized by craving for dopaminergic substances and punding (prolonged repetitive activities which are not goal-oriented).Treatment-related risk factors are dopamine agonists for ICDs and a high total dopaminergic dose for DDS and punding. Shared risk factors are young age at onset, impulsive personality traits, depression and possibly dyskinesia. At the neuronal level these behavioral disorders seem to be associated with changes in the reward system and dysfunction of the orbitofrontal cortex. The evidence level for management strategies is at present insufficient. For ICDs current clinical practice consists of discontinuation or reduction of dopamine agonists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22878676     DOI: 10.1007/s00115-012-3631-5

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  29 in total

1.  Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.

Authors:  Daniel Weintraub; Juergen Koester; Marc N Potenza; Andrew D Siderowf; Mark Stacy; Valerie Voon; Jacqueline Whetteckey; Glen R Wunderlich; Anthony E Lang
Journal:  Arch Neurol       Date:  2010-05

2.  Clozapine for medication-related pathological gambling in Parkinson disease.

Authors:  Alessandro Rotondo; Domenico Bosco; Massimiliano Plastino; Arturo Consoli; Francesca Bosco
Journal:  Mov Disord       Date:  2010-09-15       Impact factor: 10.338

3.  Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward.

Authors:  Andrew H Evans; Andrew D Lawrence; Silke Appel Cresswell; Regina Katzenschlager; Andrew J Lees
Journal:  Mov Disord       Date:  2010-05-15       Impact factor: 10.338

4.  Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling.

Authors:  Roberto Cilia; Ji Hyun Ko; Sang Soo Cho; Thilo van Eimeren; Giorgio Marotta; Giovanna Pellecchia; Gianni Pezzoli; Angelo Antonini; Antonio P Strafella
Journal:  Neurobiol Dis       Date:  2010-03-22       Impact factor: 5.996

5.  Punding and dyskinesias.

Authors:  Laura Silveira-Moriyama; Andrew H Evans; Regina Katzenschlager; Andrew J Lees
Journal:  Mov Disord       Date:  2006-12       Impact factor: 10.338

Review 6.  Treatment of pathological gambling.

Authors:  Kit Sang Leung; Linda B Cottler
Journal:  Curr Opin Psychiatry       Date:  2009-01       Impact factor: 4.741

7.  Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease.

Authors:  C W Hicks; M M Pandya; I Itin; H H Fernandez
Journal:  Parkinsonism Relat Disord       Date:  2011-04-02       Impact factor: 4.891

8.  Punding prevalence in Parkinson's disease.

Authors:  Janis M Miyasaki; Khalid Al Hassan; Anthony E Lang; Valerie Voon
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

9.  Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study.

Authors:  T D L Steeves; J Miyasaki; M Zurowski; A E Lang; G Pellecchia; T Van Eimeren; P Rusjan; S Houle; A P Strafella
Journal:  Brain       Date:  2009-04-03       Impact factor: 13.501

10.  Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome.

Authors:  Sarah J Moum; Catherine C Price; Natlada Limotai; Genko Oyama; Herbert Ward; Charles Jacobson; Kelly D Foote; Michael S Okun
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.